SCHEMBL2837452

SCHEMBL2837452

O=C(O)CCCCCCCCCCCCC=S

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.60
MAPT P10636 3/20 0.60
TSHR P16473 1/20 0.60
NFKB1 P19838 1/20 0.60
PMP22 Q01453 1/20 0.60
ABCC4 O15439 1/20 0.60
TERT O14746 3/20 0.54
PTPN1 P18031 3/20 0.54
PPARG P37231 3/20 0.54
PPARD Q03181 3/20 0.54
PPARA Q07869 3/20 0.54
BLM P54132 2/20 0.54
HSD17B10 Q99714 2/20 0.54
FABP4 P15090 2/20 0.54
F7 P08709 2/20 0.54
F3 P13726 2/20 0.54
DUSP3 P51452 2/20 0.54
PTPN7 P35236 2/20 0.54
GMNN O75496 1/20 0.54
USP2 O75604 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6889885 1.00 LMNA (0.60) LMNAMAPTTSHRNFKB1PMP22
SCHEMBL6884903 1.00 LMNA (0.60) LMNAMAPTTSHRNFKB1PMP22
SCHEMBL11739620 1.00 LMNA (0.60) LMNAMAPTTSHRNFKB1PMP22
SCHEMBL6888186 1.00 LMNA (0.60) LMNAMAPTTSHRNFKB1PMP22
SCHEMBL1923766 1.00 LMNA (0.60) LMNAMAPTTSHRNFKB1PMP22
SCHEMBL6891959 1.00 LMNA (0.60) LMNAMAPTTSHRNFKB1PMP22
SCHEMBL3652371 1.00 LMNA (0.60) LMNAMAPTTSHRNFKB1PMP22
SCHEMBL6890958 0.97
SCHEMBL6067655 0.90
SCHEMBL7640627 0.80 FAAH (0.54) LMNAMAPTABCC4TERTPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2175863-A2 SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES Eastern Virginia Medical School (US) 2010-04-21 EP claimed
WO-2009009625-A2 SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES EASTERN VIRGINIA MEDICAL SCHOOL (US) 2009-01-15 WO claimed
US-20230173077-A1 FATTY ACYL AND FATTY ETHER CONJUGATES OF REMDESIVIR AND ITS ACTIVE METABOLITES AS ANTIVIRALS AJK Biopharmaceutical, LLC 2023-06-08 US disclosed
WO-2021222807-A1 FATTY ACYL AND FATTY ETHER CONJUGATES OF REMDESIVIR AND ITS ACTIVE METABOLITES AS ANTIVIRALS AJK PHARMACEUTICAL LLC (US) 2021-11-04 WO disclosed
WO-2004008550-A2 RAPID LOW-TEMPERATURE SYNTHESIS OF QUANTUM DOTS ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230173077-A1 FATTY ACYL AND FATTY ETHER CONJUGATES OF REMDESIVIR AND ITS ACTIVE METABOLITES AS ANTIVIRALS ELOVL6, FADS2, FASN LMNA 2735/4885MAPT 3626/4885TSHR 3779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.